Deoxycholic acid

Generic Name: Deoxycholic acid

Brand Names: Belkyra, Kybella

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₄₀O_₄

CAS Number: 83-44-3

Unique Ingredient Identifier: 005990WHZZ

Background: Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures.

Indication: For improvement in appearance of moderate to severe fullness associated with submental fat in adults.

Associated Conditions: -

Associated Therapies: Submental fat removal therapy

Clinical Trials

Molecular and functional landscape of malignant serous effusions for precision oncology

A prospective, non-randomized observational clinical study at University Hospital Zurich, Spital Uster, and Kantonsspital Winterthur collected 261 fluid samples from 184 patients with metastatic solid malignancies. The study focused on feasibility, using current clinical guidelines and patient consent. Techniques included centrifugation, FACS purification, pharmacoscopy, RNA sequencing, mutational profiling, and proteomics analysis. Ethical approval was granted by the Ethics Committee of Kanton Zurich. The study aimed to integrate multi-omics data for precision oncology.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.